Lytix Biopharma announces that Verrica Pharmaceuticals Inc. will present clinical results from their ongoing Phase II clinical study with LTX-315 (VP-315) at the AAD 2023 Innovation Academy Meeting

Oslo, 3 August 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that an abstract from its licensing partner Verrica Pharmaceuticals Inc (“Verrica”) is accepted for presentation at the American Academy of Dermatology Association’s (AAD) 2023 Innovation Academy.

Verrica’s presentation is titled “VP-315, an Investigational Non-surgical Immunotherapy in Subjects with Biopsy Proven Basal Cell Carcinoma” and will highlight the antitumor activity of LTX-315 - by Verrica designated as VP-315 - as determined by clinical and histological clearance of treated BCC lesions from the Verrica’s ongoing Phase II trial. The data will be presented at the 2023 American Academy of Dermatology 2023 Innovation Academy meeting, which is being held from August 10-13, 2023, in Tampa, Florida.

Verrica has an exclusive worldwide license agreement with Lytix to develop and commercialize LTX-315 for dermatologic oncology indications and is currently performing a clinical Phase II study in patients with basal cell carcinoma (BCC). In April 2023 Verrica announced that the first patient was dosed in Part 2 of the study. The progress into Part 2 was based on positive results from the completed Part 1 of the study, where LTX-315 showed clinical evidence of activity in patients who received a higher dose range.  

Basal cell carcinoma is the most common form of cancer in the U.S., and incidence is rising worldwide. There are approximately 3-4 million diagnoses of basal cell carcinomas in the U.S. each year, with a high unmet need for new treatment options. Basal cell carcinoma is generally treated with invasive surgery to remove the tumor, which can cause pain, infection, bleeding and scarring. LTX-315 could play a significant role as part of an alternative therapeutic regimen to surgery.

Under the terms of the license agreement, Lytix was entitled to receive an upfront payment, contingent regulatory milestones based on achievement of specified development goals, and sales milestones, with aggregate payments of up to USD 111 million in total. In addition, Lytix is entitled to receive tiered royalties based on worldwide annual sales.

The focus of the 2023 AAD Innovation Academy meeting is innovations that can change how dermatology is being practiced. For more information about the conference, follow link: https://www.aad.org/member/meetings-education/ia23

To view the full announcement from Verrica, please visit https://verrica.com/press_release/verrica-pharmaceuticals-announces-acceptance-of-abstract-featuring-clinical-data-of-vp-315-for-the-treatment-of-basal-cell-carcinoma-at-the-american-academy-of-dermatology-associations-aad/